Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase NA 3Phase 1 3Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Leukemia, Myeloid, Acute 4Leukemia 4Myelodysplastic Syndromes 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Graft vs Host Disease 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Non-Malignant Neoplasm 1Neuroblastoma 1Multiple Myeloma 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Prolymphocytic 1Immunologic Deficiency Syndromes 1Hodgkin Disease 1Hematologic Neoplasms 1Anemia 1

Interventions

Dexamethasone 133Lenalidomide 58Bortezomib 56Calcium Dobesilate 43Melphalan 41carfilzomib 38pomalidomide 36Cyclophosphamide 35daratumumab 23belantamab mafodotin 21Peripheral Blood Stem Cell Transplantation 17ixazomib 16dexamethasone acetate 13Filgrastim 13Bendamustine Hydrochloride 13fludarabine phosphate 12fludarabine 12dexamethasone 21-phosphate 12Tacrolimus 12auricularum 11Whole-Body Irradiation 11liposomal doxorubicin 10iberdomide 10Prednisone 10venetoclax 9selinexor 9Mycophenolic Acid 9pembrolizumab 8isatuximab 8Cyclosporine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Multiple Myeloma × thymoglobulin × Clear all
NCT00995059 2023-01-05

Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma

Mayo Clinic

Phase 1/2 Withdrawn
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡